Bimekizumab - Psoriasis

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve bimekizumab as a treatment option for the treatment of severe plaque psoriasis in line with NICE TA723. The current Psoriasis high cost immunomodulator treatment pathway is available below.
Increased frequency of dosing is agreed for those patients with a body weight ≥ 120 kg who did not achieve complete skin clearance during induction.

Bimekizumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians).

Increased frequency of dosing is agreed for those patients with a body weight ≥ 120 kg who did not achieve complete skin clearance during induction.
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”